ACTIVATING NTRK1 GENE FUSIONS PREDICTIVE OF KINASE INHIBITOR THERAPY

摘要

Disclosed are markers, methods and assay systems for the identification of patients suspected of having cancer and/or cancer patients who are predicted to respond, or not respond to the therapeutic administration of specific chemotherapeutic regimens. Particularly, the invention provides a testing paradigm based on tumor cell samples to select cancer patients who will benefit from chemotherapy including one or more kinase inhibitor(s), as well as a paradigm to select cancer patients who will not benefit from such chemotherapy regimen.